Literature DB >> 6278353

Central excitatory properties of delta 9-tetrahydrocannabinol and its metabolites in iron-induced epileptic rats.

S A Turkanis, R Karler.   

Abstract

The effects of delta 9-tetrahydrocannabinol (delta 9-THC), two of its metabolites, 8 beta-hydroxy-delta 9-THC and 11-hydroxy-delta 9-THC, and cannabidiol were comparatively studied by means of an iron-induced cortical focal epilepsy in conscious rats with chronically implanted electrodes. delta 9-Tetrahydrocannabinol produced depression of the spontaneously firing epileptic focus, excitatory behavior, generalized after-discharge-like bursts of epileptiform polyspikes and frank convulsions. The pharmacological profiles of the two metabolites differed from that of the parent compound: 11-Hydroxy-delta 9-THC did not precipitate convulsions, but it did elicit all the other effects of delta 9-THC; the 8 beta-hydroxy derivative, on the other hand, exerted only two delta 9-THC-like effects; that is, it evoked polyspike bursts and convulsions. In contrast, cannabidiol, even in large doses (100 mg/kg) was devoid of all the effects of delta 9-THC. Furthermore, pretreatment with cannabidiol markedly altered the responses to delta 9-THC in the following ways: focal depression was partially blocked, polyspike activity was enhanced and convulsions abolished. Phenytoin pretreatment elicited similar effects, but it failed to block the delta 9-THC-induced convulsions. In general, the cannabinoids exhibit a wide spectrum of CNS effects ranging from focal depression to convulsions; specifically, however, the pharmacological profile of each agent can differ markedly; for example, the convulsant properties of delta 9-THC are not a universal characteristic of this class of drugs.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6278353     DOI: 10.1016/0028-3908(82)90204-0

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  7 in total

1.  Marijuana use and the risk of new onset seizures.

Authors:  J C Brust; S K Ng; A W Hauser; M Susser
Journal:  Trans Am Clin Climatol Assoc       Date:  1992

2.  Endocannabinoid Signaling Regulates Sleep Stability.

Authors:  Matthew J Pava; Alexandros Makriyannis; David M Lovinger
Journal:  PLoS One       Date:  2016-03-31       Impact factor: 3.240

3.  Striatal GABAergic and cortical glutamatergic neurons mediate contrasting effects of cannabinoids on cortical network synchrony.

Authors:  Carola Sales-Carbonell; Pavel E Rueda-Orozco; Edgar Soria-Gómez; György Buzsáki; Giovanni Marsicano; David Robbe
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-26       Impact factor: 11.205

4.  Cannabinoids disrupt memory encoding by functionally isolating hippocampal CA1 from CA3.

Authors:  Roman A Sandler; Dustin Fetterhoff; Robert E Hampson; Sam A Deadwyler; Vasilis Z Marmarelis
Journal:  PLoS Comput Biol       Date:  2017-07-07       Impact factor: 4.475

5.  Cannabis for the treatment of paediatric epilepsy? An update for Canadian paediatricians.

Authors:  Richard James Huntsman; Richard Tang-Wai; Bryan Acton; Jane Alcorn; Andrew William Lyon; Darrell David Mousseau; Blair Seifert; Robert Laprairie; Erin Prosser-Loose; Lumir Ondrej Hanuš
Journal:  Paediatr Child Health       Date:  2018-04-05       Impact factor: 2.253

Review 6.  Cannabidiol in the Treatment of Epilepsy: A Focused Review of Evidence and Gaps.

Authors:  Guilherme Diogo Silva; Felipe Borelli Del Guerra; Maira de Oliveira Lelis; Lécio Figueira Pinto
Journal:  Front Neurol       Date:  2020-10-19       Impact factor: 4.003

Review 7.  Cannabinoid Receptors: An Update on Cell Signaling, Pathophysiological Roles and Therapeutic Opportunities in Neurological, Cardiovascular, and Inflammatory Diseases.

Authors:  Dhanush Haspula; Michelle A Clark
Journal:  Int J Mol Sci       Date:  2020-10-17       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.